<table class="infobox infobox-institution">
<tr>
<th class="infobox-header" colspan="2">University of Utah</th>
</tr>
<tr>
<td class="infobox-image" colspan="2">
<em>University of Utah Health Sciences Center</em>
</td>
</tr>
<tr>
<td class="label">Location</td>
<td>Salt Lake City, Utah, USA</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Research University</td>
</tr>
<tr>
<td class="label">Founded</td>
<td>1850</td>
</tr>
<tr>
<td class="label">Website</td>
<td><a href="https://healthcare.utah.edu/" target="_blank">https://healthcare.utah.edu/</a></td>
</tr>
<tr>
<td class="label">Focus Areas</td>
<td>Alzheimer's Disease, Parkinson's Disease, ALS, Neuroimaging</td>
</tr>
</table>
<table class="infobox infobox-institution">
<tr>
<th class="infobox-header" colspan="2">University of Utah</th>
</tr>
<tr>
<td class="infobox-image" colspan="2">
<em>University of Utah Health Sciences Center</em>
</td>
</tr>
<tr>
<td class="label">Location</td>
<td>Salt Lake City, Utah, USA</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Research University</td>
</tr>
<tr>
<td class="label">Founded</td>
<td>1850</td>
</tr>
<tr>
<td class="label">Website</td>
<td><a href="https://healthcare.utah.edu/" target="_blank">https://healthcare.utah.edu/</a></td>
</tr>
<tr>
<td class="label">Focus Areas</td>
<td>Alzheimer's Disease, Parkinson's Disease, ALS, Neuroimaging</td>
</tr>
</table>
The University of Utah (U of U) is a leading research university located in Salt Lake City, Utah, with a distinguished history in neuroscience and neurodegenerative disease research. Founded in 1850, the university has grown to become one of the premier academic medical centers in the Mountain West region, with particular strength in Alzheimer's disease, Parkinson's disease, and ALS research["@university"].
The University's neuroscience program is headquartered within the University of Utah Health Sciences Center, which includes the School of Medicine, the Huntsman Mental Health Institute, and numerous specialized research centers. The institution has been at the forefront of understanding the molecular mechanisms underlying neurodegeneration, with significant contributions to tau protein pathology, alpha-synuclein aggregation, and mitochondrial dysfunction in neurons["@universitya"].
The University of Utah's involvement in neuroscience research dates back to the mid-20th century, but the program experienced significant expansion in the 1980s and 1990s with the establishment of specialized centers focused on neurodegenerative diseases. The university's geographic position in the Intermountain West has enabled unique research opportunities, including population-based studies and access to diverse patient cohorts.
Key milestones in the university's neurodegenerative research history include:
The University of Utah maintains a comprehensive Alzheimer's disease research program through its Alzheimer's Disease Center, one of only 33 NIH-funded Alzheimer's Disease Research Centers in the United States. The center focuses on:
The university has established a leading program in tau protein research, investigating the spread of neurofibrillary tangles throughout the brain as Alzheimer's disease progresses. Dr. Emily Ivanova's work using novel PET radiotracers has enabled visualization of tau pathology in living patients[@ivanova2023]. This research has revealed that tau deposition follows a characteristic pattern, beginning in the entorhinal cortex and spreading to the hippocampus and neocortex. The ability to track tau accumulation in vivo has transformed clinical trials, enabling researchers to assess whether experimental therapies are hitting their target.
A major focus of the Alzheimer's program involves understanding the contribution of neuroinflammation to disease pathogenesis. Dr. O'Banion's laboratory has demonstrated that chronic activation of microglia contributes to synaptic loss and cognitive decline[@obanion2024]. Studies by Dr. Williams have characterized distinct microglial activation states in Alzheimer's disease brain tissue, revealing that some microglial phenotypes may be protective while others contribute to pathology[@williams2023].
Research on amyloid-beta and apolipoprotein E (APOE) represents another major focus. Studies by Dr. Martinez have examined how different APOE genotypes influence Alzheimer's disease risk and response to therapy[@martinez2024]. The university's biorepository contains samples from carriers of various APOE alleles, enabling detailed investigation of how APOE affects amyloid metabolism, neuroinflammation, and neuronal vulnerability.
The university's Parkinson's disease program encompasses basic science, translational, and clinical research:
Dr. Yang Zhou leads the university's alpha-synuclein research program, investigating how this protein aggregates and spreads throughout the nervous system in Parkinson's disease[@zhou2024]. His work has demonstrated that pathological forms of alpha-synuclein can propagate from cell to cell, spreading neurodegeneration throughout the brain. This research has implications for developing therapies that might block alpha-synuclein propagation.
The university participates in the International Parkinson's Disease Genetics Consortium, investigating genetic causes of Parkinson's disease. Studies by Dr. Singh have characterized the clinical phenotypes associated with LRRK2 mutations, revealing that LRRK2 carriers may have distinct clinical features compared to sporadic Parkinson's disease[@singh2023].
Research by Dr. Kim has focused on the biomarkers and mechanisms underlying Parkinson's disease dementia[@kim2024]. His work has identified CSF and imaging markers that may predict which patients will develop cognitive impairment, enabling earlier intervention.
The University of Utah has a strong ALS research program focusing on:
Research by Dr. Taylor has characterized TDP-43 pathology in ALS and frontotemporal dementia[@taylor2023]. TDP-43 is the major protein accumulating in motor neurons of ALS patients, and understanding its aggregation may lead to novel therapeutic approaches.
Dr. Thompson leads efforts to identify novel therapeutic targets for ALS[@Thompson2024]. His work has focused on the cellular stress pathways that become dysregulated in motor neurons, identifying potential drug targets that may slow disease progression.
The Huntsman Mental Health Institute represents a major investment in neuroscience research at the University of Utah. This state-of-the-art facility houses researchers studying the intersection of mental health and neurodegenerative diseases, with particular emphasis on depression and anxiety in Alzheimer's and Parkinson's disease patients.
CACIR serves as the hub for Alzheimer's disease research, combining clinical care, neuroimaging research, and biomarker development. The center maintains a large biorepository of brain tissue and CSF samples, supporting numerous research projects investigating disease mechanisms and therapeutic targets.
The university's PET imaging center provides access to cutting-edge radiotracers for neuroimaging research, enabling visualization of amyloid plaques, tau tangles, and neurotransmitter systems in living patients[@ivanova2023; @wang2024]. The center participates in multi-site studies that validate new radiotracers and establish imaging biomarkers for clinical use.
The Center for Integrative Neuroscience brings together researchers from multiple disciplines to study brain function and dysfunction. This center provides infrastructure for systems neuroscience research that complements the cellular and molecular approaches used in neurodegeneration research.
Recognizing the importance of big data in modern neuroscience research, the university has established a bioinformatics core that supports analysis of genomic, proteomic, and imaging data. This resource enables researchers to integrate multiple data types to understand disease mechanisms.
| Researcher | H-index | Focus Areas |
|------------|---------|-------------|
| Dr. Stefan M. Pulst | 90 | ALS, Ataxias, Genetic Neurodegeneration [@pulst2023] |
| Dr. John R. O'Banion | 85 | Alzheimer's Disease, Neuroinflammation [@obanion2024] |
| Dr. Richard B. Dewey | 70 | Parkinson's Disease, Movement Disorders [@dewey2023] |
| Dr. Kevin J. Flood | 55 | Neuroimaging, Biomarkers [@flood2024] |
| Dr. Emily Ivanova | 45 | Tau PET Imaging [@ivanova2023] |
| Dr. Yang Zhou | 50 | Alpha-Synuclein Biology [@zhou2024] |
Dr. Stefan Pulst serves as one of the nation's leading experts on the genetic mechanisms of ALS and hereditary ataxias. His research has identified novel mutations in the TDP-43 protein that contribute to motor neuron degeneration[@pulst2023]. The Pulst laboratory has pioneered the use of induced pluripotent stem cells (iPSCs) to model neurodegenerative diseases, enabling researchers to study disease mechanisms in patient-derived neurons.
Dr. O'Banion's research focuses on the role of neuroinflammation in Alzheimer's disease pathogenesis. His work has demonstrated that chronic microglial activation contributes to neuronal dysfunction and memory impairment[@obanion2024]. His laboratory investigates anti-inflammatory therapeutic approaches that may slow disease progression without compromising essential immune functions.
Dr. Dewey has pioneered advances in deep brain stimulation therapy for Parkinson's disease. His research on optimal stimulation parameters and target selection has improved outcomes for patients undergoing DBS surgery[@dewey2023]. His work also addresses non-motor symptoms of Parkinson's disease, including cognitive impairment and mood disorders.
Dr. Flood leads the university's neuroimaging research program, developing novel MRI and PET techniques for early detection of Alzheimer's disease[@flood2024]. His work on white matter imaging has revealed previously undetectable changes in brain connectivity that occur early in the disease process.
The University of Utah actively participates in numerous clinical trials for neurodegenerative diseases:
The University of Utah offers comprehensive training programs in neurodegenerative disease research:
The University of Utah maintains active collaborations with leading institutions worldwide:
Researchers at the University of Utah have contributed to several important discoveries in neurodegenerative disease research:
Research by Dr. Liu has focused on mitochondrial dysfunction as a common mechanism in neurodegenerative diseases[@liu2023]. Mitochondria generate cellular energy and their dysfunction leads to energy failure, oxidative stress, and neuronal death. Studies from the Liu laboratory have identified therapeutic approaches that preserve mitochondrial function in models of Alzheimer's and Parkinson's disease.
Dr. Anderson's research on white matter hyperintensities has revealed that these imaging markers are associated with cognitive decline and predict progression from mild cognitive impairment to Alzheimer's disease[@anderson2023]. This work has implications for using MRI as a prognostic tool and for understanding the vascular contributions to neurodegeneration.
The university has launched a precision medicine initiative for neurodegenerative diseases, aiming to tailor diagnostic and therapeutic approaches to individual patient characteristics. Research by Dr. Robinson has examined how genetic profiles, biomarker signatures, and clinical phenotypes can predict disease course and treatment response[@robinson2024]. This approach represents a shift from one-size-fits-all treatment to personalized medicine.
The University of Utah continues to expand its neurodegeneration research program with a focus on: